PI-1840

has both antineoplastic and proteasome inhibitory activities; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 04/25/2014 - "Furthermore, PI-1840 sensitizes human cancer cells to the mdm2/p53 disruptor, nutlin, and to the pan-Bcl-2 antagonist BH3-M6. " 04/25/2014 - "In intact cancer cells, PI-1840 inhibits CT-L activity, induces the accumulation of proteasome substrates p27, Bax, and IκB-α, inhibits survival pathways and viability, and induces apoptosis. " 04/25/2014 - "Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity."
2.	Breast Neoplasms (Breast Cancer) 04/25/2014 - "Finally, in vivo, PI-1840 but not bortezomib suppresses the growth in nude mice of human breast tumor xenografts. "

1.	Proteasome Inhibitors
2.	Proteasome Endopeptidase Complex (Proteasome)
3.	Bortezomib (Velcade)